D Körholz

Universitätsklinikum Halle (Saale), Halle-on-the-Saale, Saxony-Anhalt, Germany

Are you D Körholz?

Claim your profile

Publications (172)532.12 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Nodular lymphocyte-predominant Hodgkin lymphoma (nLPHL) is a very rare disease in childhood and adolescence. In Germany, about 15 newly diagnosed patients present with this disease annually; this number comprises less than 10% of all pediatric Hodgkin lymphoma cases. Since the EuroNet-PHL-LP1 trial for early stage nLPHL patients stopped recruiting in Germany in October 2014, the GPOH-HD writing committee reviewed the literature and decided to deliver treatment recommendations for childhood and adolescent nLPHL patients. These guidelines shall be applicable to young nLPHL patients in European countries that will no longer be able to participate in nLPHL trials for young patients. Therefore, the EuroNet-PHL-nLPHL-registry will be installed to provide quality assured central review of staging and response assessment for registered patients by the Central Review Board of EuroNet-PHL in Halle/Leipzig, Germany.
    Klinische Pädiatrie 09/2015; DOI:10.1055/s-0035-1559664 · 1.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hodgkin lymphoma (HL) is one of the most curable pediatric and adult cancers, with long-term survival rates now exceeding 90% after treatment with chemotherapy alone or combined with radiotherapy (RT). Of note, global collaboration in clinical trials within cooperative pediatric HL study groups has resulted in continued progress; however, survivors of pediatric HL are at high risk of potentially life-limiting second cancers and treatment-associated cardiovascular disease. Over the last three decades, all major pediatric and several adult HL study groups have followed the paradigm of response-based treatment adaptation and toxicity sparing through the reduction or elimination of RT and tailoring of chemotherapy. High treatment efficacy is achieved using dose-dense chemotherapy. Refinement and reduction of RT have been implemented on the basis of results from collaborative group studies, such that radiation has been completely eliminated for certain subgroups of patients. Because pediatric staging and response criteria are not uniform, comparing the results of trial series among different pediatric and adult study groups remains difficult; thus, initiatives to harmonize criteria are desperately needed. A dynamic harmonization process is of utmost importance to standardize therapeutic risk stratification and response definitions as well as improve the care of children with HL in resource-restricted environments. © 2015 by American Society of Clinical Oncology.
    Journal of Clinical Oncology 08/2015; DOI:10.1200/JCO.2014.59.4853 · 18.43 Impact Factor
  • Lars Kurch · Regine Kluge · Thomas Georgi · Dieter Körholz
    [Show abstract] [Hide abstract]
    ABSTRACT: Paediatric lymphomas are rare diseases. Uniform treatment protocols are therefore important to transnationally support standardised and comparable therapy strategies. Within these protocols, FDG-PET/CT has its fixed position for staging and early response assessment in paediatric Hodgkin’s lymphoma (P-HL) since several years. However, the role of FDG-PET/CT in paediatric non-Hodgkin’s lymphoma protocols is not well defined and large international cross-centre trials are still missing. The article therefore nearly exclusively focuses on the role of FDG-PET/CT in P-HL patients in Europe.
    08/2015; DOI:10.1007/s40336-015-0126-y
  • Klinische Pädiatrie 11/2014; 226(6-7):307-8. DOI:10.1055/s-0034-1389928 · 1.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract The GPOH-HD strategy for children and adolescents with intermediate and advanced stage Hodgkin`s lymphoma (HL) is based on two induction cycles OEPA followed by COPP or COPDAC consolidation. Feasibility and efficacy of an intensified procarbazine-free consolidation regime VECOPA were investigated. Following two OEPA and one or two VECOPA cycles involved field radiotherapy was applied. Main endpoint was feasibility; secondary endpoints were toxicity, proportion of delayed cycles, G-CSF use, event-free and overall survival. The regimen was well tolerable with mostly haematotoxicity exceeding CTC grade 2. In most advanced stage patients the 2(nd) VECOPA cycle was delayed despite hematopoietic recovery and absence of SAEs. EFS at 36 months was 0.86 [0.70 - 1] (95%CI). The VECOPA regime is effective and tolerable; however its time-intensification was not fully exploited within this trial.
    Leukemia and Lymphoma 09/2014; 56(5):1-17. DOI:10.3109/10428194.2014.961011 · 2.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Interdisciplinary cooperation and networking determine the success of activities for supporting families at risk for early childhood abuse. The integration of the healthcare sector might be important.The medical standard of perinatal care at the University hospital includes information exchange about family risk factors which may contribute to an increased risk of child abuse within the first year of life. As a result, the -pediatrician offered supporting services for the families at the time of the second examination during the official childhood health screening program (U2). A team of family-sponsorship was established and evaluated.In 281 of 1 238 risk-factor questionnaires at least one stress factor was detected and 97 families had high-impact family stress. Families under the supervision of a family midwife or youth services had a significantly higher number of risk factors. The family-sponsorship program was institutionalized and positively evaluated by the families.The time of a hospital delivery is an excellent opportunity for the evaluation of familial risk factors and for the provision of supporting services. To increase the acceptance of such services by the families at risk repeated assessment of risk factors and support offers are required.
    Klinische Pädiatrie 07/2014; 226(4):243-247. DOI:10.1055/s-0034-1374603 · 1.06 Impact Factor
  • Klinische Pädiatrie 03/2014; 226(02). DOI:10.1055/s-0034-1371165 · 1.06 Impact Factor
  • Klinische Pädiatrie 03/2014; 226(02). DOI:10.1055/s-0034-1371126 · 1.06 Impact Factor
  • A Fink · C Mauz-Körholz · D Körholz · M Richter
    Klinische Pädiatrie 03/2014; 226(02). DOI:10.1055/s-0034-1371167 · 1.06 Impact Factor
  • Klinische Pädiatrie 03/2014; 226(02). DOI:10.1055/s-0034-1371131 · 1.06 Impact Factor
  • Klinische Pädiatrie 03/2014; 226(02). DOI:10.1055/s-0034-1371171 · 1.06 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Interim FDG-PET is used for treatment tailoring in lymphoma. Deauville response criteria consist of five ordinal categories based on visual comparison of residual tumor uptake to physiological reference uptakes. However, PET-response is a continuum and visual assessments can be distorted by optical illusions. With a novel semi-automatic quantification tool we eliminate optical illusions and extend the Deauville score to a continuous scale. SUVpeak of residual tumors and average uptake of the liver is measured with standardized volumes of interest. The qPET value is the quotient of these measurements. Deauville scores and qPET-values were determined in 898 pediatric Hodgkin's lymphoma patients after two OEPA chemotherapy cycles. Deauville categories translate to thresholds on the qPET scale: Categories 3, 4, 5 correspond to qPET values of 0.95, 1.3 and 2.0, respectively. The distribution of qPET values is unimodal with a peak representing metabolically normal responses and a tail of clearly abnormal outliers. In our patients, the peak is at qPET = 0.95 coinciding with the border between Deauville 2 and 3. qPET cut values of 1.3 or 2 (determined by fitting mixture models) select abnormal metabolic responses with high sensitivity, respectively, specificity. qPET methodology provides semi-automatic quantification for interim FDG-PET response in lymphoma extending ordinal Deauville scoring to a continuous scale. Deauville categories correspond to certain qPET cut values. Thresholds between normal and abnormal response can be derived from the qPET-distribution without need for follow-up data. In our patients, qPET < 1.3 excludes abnormal response with high sensitivity.
    European Journal of Nuclear Medicine 03/2014; 41(7). DOI:10.1007/s00259-014-2715-9 · 5.38 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Sequencing of individual clones from a newly established cDNA library from the chemoresistant Hodgkin's lymphoma cell line L-1236 led to the isolation of a cDNA clone corresponding to a short sequence from chromosome 1. Reverse transcriptase-polymerase chain reaction indicated high expression of this sequence in Hodgkin's lymphoma derived cell lines but not in normal blood cells. Further characterization of this sequence and the surrounding genomic DNA revealed that this sequence is part of a human endogenous retrovirus locus. The sequence of this endogenous retrovirus is interrupted by a pseudogene of the dual specificity phosphatase 5 (DUSP5). Reverse transcriptase-polymerase chain reaction revealed high expression of this pseudogene (DUSP5P1) in HL cell lines but not in normal blood cells or Epstein-Barr virus-immortalized B cells. Cells from other tumor types (Burkitt's lymphoma, leukemia, neuroblastoma, Ewing sarcoma) also showed a higher DUSP5P1/DUSP5 ratio than normal cells. Furthermore, we observed that higher expression of DUSP5 in relation to DUSP5P1 correlated with the expression of the pro-apoptotic factor B cell leukemia/lymphoma 2-like 11 (BCL2L11) in peripheral blood cells and HL cells. Knock-down of DUSP5 in HL cells resulted in down-regulation of BCL2L11. Thus, the DUSP5/DUSP5P1 system could be responsible for regulation of BCL2L11 leading to inhibition of apoptosis in these tumor cells.
    PLoS ONE 02/2014; 9(2):e89577. DOI:10.1371/journal.pone.0089577 · 3.23 Impact Factor
  • G Jorch · D Körholz · L Gortner
    Klinische Pädiatrie 12/2013; 225(7):377-8. DOI:10.1055/s-0033-1358724 · 1.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cancer is linked to defects in immunosurveillance. Vaccination studies using dendritic cells (DC) try to re-establish immune responses toward tumor cells. Tumor-derived products such as interleukin-10 (IL-10) have inhibitory effects on DC function, and tumor-bearing hosts exhibit a lower number of DCs, suggesting inhibitory effects of tumor-derived factors on the recruitment of precursor cells. We generated DCs in the presence and absence of IL-10. DCs were then characterized by flow cytometry and cDNA microarray analysis. IL-10 interferes with differentiation of peripheral blood monocytes to DCs and induces cells with a distinct phenotype. Microarray analysis revealed that IL-10 exhibits inhibitory as well as stimulatory effects on the expression of several genes. Addition of IL-10 to the differentiation cocktail induces a sustained inhibitory effect on subsequent maturation stimuli. IL-10 inhibits DC function and redirects differentiation of DCs to cells with a different phenotype, thereby reducing the pool of potential DC precursors.
    Anticancer research 11/2013; 33(11):4791-8. · 1.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Since 2007, children and adolescents with Hodgkin lymphomas are treated in the Europe-wide EuroNet-PHL trials. A real time central review process for stratification of the patients enhances quality control and efficient therapy management. This process includes reading of all cross-sectional-images. Since reference evaluation is time critical, a fast, easy to handle and safe data transfer is important. In addition, immediate and constant access to all the data has to be guaranteed in case of queries and for regulatory reasons. To meet the mentioned requirements the EuroNet Paediatric Hodgkin Data Network (funded by the European Union - Project Number: 2007108) was established between 2008 and 2011. A respective tailored data protection plan was formulated. The aim of this article is to describe the networks' mode of operation and the advantages for multi-centre trials that include centralized image review.
    Klinische Pädiatrie 10/2013; 225(6). DOI:10.1055/s-0033-1354416 · 1.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Further survival improvements of adolescents and young adults (AYA) with cancer are clearly affected by biological characteristics of the malignancies and age-specific needs. Multidisciplinary teams drawing expertice from both pediatric and adult cancer teams as well as clinical trials are required to meet the age specific needs of AYA patients with cancer. In 2011, the first AYA unit was established at the University Hospital Halle (Saale), where patients with newly-diagnosed cancer aged 15-25 are treated interdisciplinary by pediatric and adult oncologists. The enrollment into pediatric or adult clinical trials is controlled by age 18. Over the last 2 years, 19 AYA with cancer have been treated at the unit; and, in turn patients and their relatives reflected a high satisfaction with the offered novel health care approach. In the scope of the future Comprehensive Cancer Center at the University Hospital Halle (Saale), a complete ward is planned for all admitted AYA up to 25 years with cancer. The patients will be treated by a tumor-specialized multidisciplinary team of adult or pediatric oncologists and oncological surgeons. Therefore, we intend to establish a special teaching curriculum for physicians, nurses and psychosocial health care staff. Rather than age, cancer biology of a malignancy, surveillance data of late side effects as well as the age-specific needs of AYA patients will be crucial for best treatment options.
    Klinische Pädiatrie 10/2013; 225(6). DOI:10.1055/s-0033-1358663 · 1.06 Impact Factor
  • R Haase · D Worlitzsch · F Schmidt · R Kulka · A S Kekulé · D Körholz
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: In the last years the prevalence of multi-resistant pathogens (MRPs) has increased. Systemic infections remain important for neonatal morbidity and mortality. Patients: Neonates born between January 2011 and December 2012 and admitted to the neonatology before their tenth day of life were included into this retrospective analysis. Vancomycin-resistant Enterococci, Methicillin-resistant Staphylococcus aureus, Gram-negative bacilli with Extend Spectrum Beta Lactamase or AMP-C resistance were defined as multi-resistant pathogens (MRPs). MRP positive and negative patients were analyzed regarding clinical risk factors and the incidence of systemic infections. Results: 635 neonates were admitted during the analysis period. In 31 patients MRPs were detected. 2 patients developed MRP-associated infections. Both were discharged without long term health risks. Low gestational age and need for mechanical ventilation were risk factors for colonization with MRPs in the univariat analysis. The incidence density (per 1 000 patient days) for all MRE increased from 0.76 in 2011 to 3.51 in 2012. In contrast the sepsis rate remained stable (14.9% and 14.2%). 2 MRP colonization clusters were detected by routine microbiology swabs. Both could be controlled by appropriate hygienic measures. Conclusions: The prevalence of Gram-negative MRPs increased in neonates. Microbiological screening seems to be helpful for early detection of colonization and thus prevention of nosocomial infections with MRPs. Despite the increased attention towards the problems associated with multiresistant bacteria, there are still major efforts needed for prevention and early treatment of sepsis with non-resistant bacteria.
    Klinische Pädiatrie 10/2013; 226(1). DOI:10.1055/s-0033-1354376 · 1.06 Impact Factor
  • D Körholz · L Gortner · U Göbel
    Klinische Pädiatrie 07/2013; 225(4):191-192. DOI:10.1055/s-0033-1349119 · 1.06 Impact Factor
  • R Haase · P Voigt · A Kekulé · D Worlitzsch · F Schmidt · D Körholz
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Microbiological screening (MS) is standard on neonatal intensive care units (NICU). Objectives are the collection of information regarding bacterial pathogens of the individual patient as well as of the NICU, especially of multidrug-resistant pathogens (MRE). The role of microbiological screening for preterm infants ≤32 weeks of gestational age has not been fully evaluated. Patients and methods: For preterm infants ≤32 weeks of gestational age admitted during a 41-month period the results of microbiological screening during the first 2 weeks of life were analysed retrospectively. The results were associated with documented septic episodes. Results: Bacteria were isolated in 215/972 of postnatal and 416/862 of later swabs. Detection of bacteria in the initial MS was associated with vaginal birth, low gestational age, low APGAR values at 5 and 10 min and mechanical ventilation. The proportion of patients with positive microbiological screening in subsequent swabs was not influenced by gestational age, birth weight, sex, mode of delivery and APGAR score. During the observation period 52 cases of sepsis (28 clinic, 24 microbiological) occurred. The sepsis rate was increased in patients with positive postnatal swabs, low gestational age, low birth weight, low 5 min APGAR score, male sex or need for mechanical ventilation. Conclusions: Microbiological screening provides an overview of the NICU-specific pathogens but is of limited value in the prediction of septicaemias in preterm infants ≤32 weeks gestational age.
    Zeitschrift für Geburtshilfe und Neonatologie 04/2013; 217(2):56-60. DOI:10.1055/s-0033-1341451 · 0.48 Impact Factor

Publication Stats

2k Citations
532.12 Total Impact Points


  • 2011–2014
    • Universitätsklinikum Halle (Saale)
      Halle-on-the-Saale, Saxony-Anhalt, Germany
  • 2008–2014
    • Martin Luther University Halle-Wittenberg
      • Clinic for Paediatric and Adolescent Medicine
      Halle-on-the-Saale, Saxony-Anhalt, Germany
  • 1999–2014
    • University of Leipzig
      • Department für Nuklearmedizin
      Leipzig, Saxony, Germany
    • University of Hamburg
      Hamburg, Hamburg, Germany
  • 1989–2009
    • Heinrich-Heine-Universität Düsseldorf
      • • Kinderklinik
      • • Klinik für Hämatologie, Onkologie und Klinische Immunologie
      Düsseldorf, North Rhine-Westphalia, Germany
  • 2007
    • Gesellschaft für Pädiatrische Onkologie und Hämatologie
      Leipzig, Saxony, Germany
  • 2006
    • Diabetes Clinic for Children and Adolescents
      Muenster, North Rhine-Westphalia, Germany
  • 2003
    • VU University Medical Center
      Amsterdamo, North Holland, Netherlands
  • 2000
    • University of Münster
      Muenster, North Rhine-Westphalia, Germany
  • 1988–1996
    • Universitätsklinikum Düsseldorf
      Düsseldorf, North Rhine-Westphalia, Germany